A.M. Best to Participate in 10th Anniversary World Takaful Conference

LONDON--(BUSINESS WIRE)-- A.M. Best will participate as a ratings’ partner sponsor and exhibitor at the 10th Anniversary World Takaful Conference, to be held 13-14 April in Dubai.

Mahesh Mistry, director, analytics, will take part in a session on “Sustainable Market Growth—Looking at the Opportunities for Innovating the Takaful Market Offering” on 13 April. Mr. Mistry will deliver a presentation on “Catalysts for Growth for the Next Decade and Review of the Development of GCC (re)Takaful Rating Fundamentals.” On 14 April, Salman Siddiqui, financial analyst, will also participate in a panel session, “Ratings Roundtable: Improving Financial Strength of Takaful Players—What Can Be Done?”

A.M. Best currently rates a number of Takaful companies and has specific Takaful rating criteria, which can be found at http://www.ambest.com/ratings/methodology/takafulinsurance.pdf.

To learn more about Best’s Credit Ratings, please visit Best’s Ratings and Criteria Center at http://www.ambest.com/ratings.

To arrange a meeting with A.M. Best representatives at the 10th Anniversary World Takaful Conference, please e-mail Bouchra Abou Nader at [email protected].

Information about the conference is available at http://www.worldtakaful.megaevents.net.

A.M. Best Europe – Rating Services Limited is a subsidiary of A.M. Best Company. A.M. Best Company is the world's oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2015 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

A.M. Best
Charlotte Jackson, +(44) 20 7626 6264
[email protected]

Source: A.M. Best

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LONGi at UNCCD COP17: Li Zhenguo Explains Two Technological Pathways for PV-Powered Food Security
• Best’s Market Segment Report: Asia-Pacific Reinsurers Show Resilience Amid Evolving Market Landscapes
• Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease